A new review considers how SGLT2 inhibitors like dapagliflozin and empagliflozin have been shown to clinically improve gout while reducing its cardiometabolic and renal comorbidities.
1. Combination therapy of empagliflozin and citalopram reduced symptom severity in patients with major depressive disorder. 2. This average reduction in symptom severity was statistically significant over time in comparison to the reduction of symptoms seen in the placebo-citalopram group. Evidence Rating Level: 1 (Excellent) Antidepressants like selective serotonin reuptake inhibitors (SSRIs) are presently first-line
Findings were presented at The Liver Meeting 2023 from the American Association for the Study of Liver Diseases and showed empagliflozin reduced liver fat content in both patients with T2DM and nondiabetic patients.
Data shows sodium-glucose cotransporter-2 (SGLT2) inhibitors are efficacious and can be used in almost all common kidney diagnoses, explained William G. Herrington, MD, MA, MBBS, Nuffield Department of Population Health, University of Oxford.